Department of Surgery, Division of Vascular Surgery, Oregon Health and Science University, Portland, OR 97239-3098, USA.
J Vasc Surg. 2013 Jul;58(1):25-31. doi: 10.1016/j.jvs.2012.12.046. Epub 2013 Mar 7.
Lifelong surveillance is recommended for both endovascular aneurysm repair and acute, uncomplicated type B thoracic aortic dissection, though compliance remains a significant challenge. We sought to determine factors associated with failure to obtain recommended surveillance.
Patients surviving to discharge who had endovascular repair of thoracic (thoracic endovascular aortic aneurysm repair [TEVAR]) or abdominal aortic aneurysms (endovascular aortic aneurysm repair [EVAR]) or medical management for type B dissections from 2004-2011 were reviewed. Primary end points were compliance with follow-up and need for reintervention. Comorbidities examined included coronary artery disease, congestive heart failure, hypertension, chronic obstructive pulmonary disease, diabetes, and chronic kidney disease. Socioeconomic factors examined were age, sex, distance from hospital, discharge destination (ie, home or skilled nursing facility), and insurance type. Endoleak and sac expansion were recorded, as were complications, including endograft migration, infection or thrombosis, and aneurysm degeneration.
Two hundred four patients, median age 71.9 years, were identified; 171 had EVAR and 33 had type B dissection. EVAR patients included 45 thoracic, 100 abdominal, and 12 thoracoabdominal endografts, as well as 7 iliac artery aneurysm repairs and 7 proximal/distal graft extensions. Median follow-up was 28 ± 10.5 months. Overall, 56% were lost to follow-up, whereas 11% never returned for surveillance after initial hospitalization. Follow-up was compared for each of the comorbidities and socioeconomic factors; none were found to significantly affect follow-up. The known complication rate was 9.3% (n = 19), with reintervention performed in 14% of EVAR/TEVAR patients. Thirty-eight percent of medically managed patients with type B dissections eventually required surgical intervention. All-cause 5-year mortality was 27% as determined by the Social Security Death Index.
Despite a significant rate of reintervention following EVAR, TEVAR, and type B dissection, long-term compliance with surveillance is limited. In addition, predicting who is at risk of being lost to follow-up remains difficult. If current recommendations for lifelong surveillance are to be followed, coordinated protocols are required to capture EVAR, TEVAR, and type B dissection patients to ensure optimal follow-up for these patients. However, the lack of survival benefit in those with complete follow-up suggests that further study is needed with regard to ideal duration of long-term follow-up.
对于血管内动脉瘤修复术和急性非复杂性 B 型胸主动脉夹层,建议进行终身监测,但遵守情况仍然是一个重大挑战。我们试图确定与未获得推荐监测相关的因素。
对 2004 年至 2011 年间接受胸主动脉(胸主动脉血管内修复术 [TEVAR])或腹主动脉瘤血管内修复术(血管内主动脉瘤修复术 [EVAR])或 B 型夹层的药物治疗的幸存至出院的患者进行了回顾性分析。主要终点是遵循随访和需要再次干预的情况。检查的合并症包括冠状动脉疾病、充血性心力衰竭、高血压、慢性阻塞性肺疾病、糖尿病和慢性肾脏病。检查的社会经济因素包括年龄、性别、与医院的距离、出院目的地(即家庭或熟练护理设施)和保险类型。记录了内漏和囊腔扩张,以及并发症,包括移植物迁移、感染或血栓形成和动脉瘤退化。
确定了 204 名患者,中位年龄为 71.9 岁;171 名患者接受了 EVAR,33 名患者患有 B 型夹层。EVAR 患者包括 45 例胸主动脉、100 例腹主动脉和 12 例胸腹主动脉内支架,以及 7 例髂动脉瘤修复和 7 例近端/远端移植物延伸。中位随访时间为 28 ± 10.5 个月。总体而言,有 56%的患者失访,而有 11%的患者在首次住院后从未返回进行监测。对每个合并症和社会经济因素进行了随访比较;没有发现任何因素显著影响随访。已知的并发症发生率为 9.3%(n = 19),EVAR/TEVAR 患者中有 14%需要再次干预。38%的接受药物治疗的 B 型夹层患者最终需要手术干预。通过社会安全死亡指数确定的所有原因 5 年死亡率为 27%。
尽管 EVAR、TEVAR 和 B 型夹层后再次干预的比例较高,但长期遵守监测的情况仍然有限。此外,预测谁有失访的风险仍然很困难。如果要遵循目前对终身监测的建议,就需要制定协调的方案来捕获 EVAR、TEVAR 和 B 型夹层患者,以确保为这些患者提供最佳的随访。然而,在完全遵循随访的患者中缺乏生存获益表明,需要进一步研究确定长期随访的理想持续时间。